What is the current stock price of Axsome Therapeutics, Inc. (AXSM)?

As of the latest market data, Axsome Therapeutics, Inc. (AXSM) is trading at $234.52. The stock has seen a gain of 0.14% today.

Does Axsome Therapeutics, Inc. (AXSM) pay a dividend?

Based on current data, Axsome Therapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Axsome Therapeutics, Inc.?

The current market capitalization of Axsome Therapeutics, Inc. (AXSM) is approximately unavailable.

AXSM

Axsome Therapeutics, Inc.·Healthcare

234.52

0.137%(+0.32)

Close Price

237.99

1.480%(+3.47)

Pre-Market

Last Updated: — ET

52W L: $96.0952W H: $238.56

AXSM NEWS

globenewswire.com

23h ago

Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in June:

globenewswire.com

23h ago

Axsome Therapeutics to Participate in Upcoming Investor Conferences

globenewswire.com

1d ago

Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new AUVELITY® data in major depressive disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting being held from May 26-29 in Miami, FL. Details of the presentations are as follows: Title: Effects of Dextromethorphan-Bupropion (45 mg/105 mg) in Participants with Major Depressive Disorder and Anxious Distress Presentation Date and Time: Wednesday, May 27, 11:45 a.m.

marketbeat.com

May 12

Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer's Agitation Launch

Axsome Therapeutics NASDAQ: AXSM executives said the company is preparing for a June launch of AUVELITY in Alzheimer's disease agitation while continuing to expand its push in major depressive disorder, citing broad payer access, a larger sales force and what they described as a differentiated clinical profile.

seekingalpha.com

May 12

Axsome Therapeutics, Inc. (AXSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

fool.com

May 8

3 Stocks Poised to Disrupt the Healthcare Market by 2030

The old healthcare model is breaking down.

Company Profile

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Sector

Healthcare

Industry

Biotechnology

Employees

712

IPO Date

2015-11-19

Beta

0.58

Websitewww.axsome.com↗